Dr. Anand Participated in Research on New Gene Therapy Drug for X-linked Retinitis Pigmentosa Published in American Journal of Ophthalmology
The two-year results of the Phase I/II, multi-center HORIZON clinical trial of the new subretinal gene therapy drug AGTC-501 for X-linked retinitis pigmentosa were recently published in the American Journal of Ophthalmology.
read more
Dr. Coors Treats First Patient in DAYBREAK Clinical Trial of Intravitreal Tarcocimab Tedromer and Tabirafusp Tedromer for Wet AMD
Texas Retina’s Lori E. Coors, MD, recently enrolled and treated the first patient in the Phase III DAYBREAK trial evaluating an intravitreal tarcocimab tedromer and tabirafusp tedromer compared with intravitreal aflibercept in
read more
Dr. Anand Presented Interim Study Results of New Gene Therapy for X-linked Retinitis Pigmentosa at ASRS 2024 Annual Meeting
Texas Retina’s Rajiv Anand, MD, presented “Subretinal AGTC-501 Gene Therapy for XLRP: 12-Month Interim Safety & Efficacy Results of the Randomized Controlled Multicenter Phase II Skyline Trial” at the 2024 Annual Meeting
read more
Kimberly Jones Recognized for 26+ Years of Service to Texas Retina
We are continuing to celebrate our team members who have been a part of the Texas Retina family for 20 years or more. Today we recognize Kimberly Jones who joined our team
read more
Honoring Our Physicians
Tomorrow, March 30, is National Doctor’s Day. At Texas Retina, we celebrate all 16 of our physicians as well as all of the physicians who care for our patients and communities. Thank
read more